SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E

Kura Oncology, Inc. · 8-K filed Sep 8, 2026 at 07:05 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Sep 8, 2026 at 07:05 ET

Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E. Wilson and Thomas Doyle in those roles, effective September 8, 2026. This is a routine executive appointment with standard compensation terms, including a $550,000 base salary, an option for 450,000 shares, and a performance-based RSU award. No red flags such as unexpected departures or resignations are present, making this a neutral event.

  • Jennifer Fulk appointed CFO, principal financial officer, and principal accounting officer effective September 8, 2026.
  • Annual base salary of $550,000, with eligibility for an annual discretionary bonus of up to 45% of base salary.
  • Received an option to purchase 450,000 shares vesting over 4 years and a performance-based RSU award covering 173,438 shares.
  • No unexpected departures or resignations; the appointment is a standard executive change.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access